|
Health care resource utilization (HCRU) in relapsed/refractory multiple myeloma (RRMM): Results from PREAMBLE. |
|
|
Honoraria - Celgene; Chugai Pharma; Janssen; Millennium; Novartis; Onyx |
Consulting or Advisory Role - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Janssen (Inst); Novartis (Inst); Onyx (Inst); Takeda (Inst) |
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma (Inst); Janssen (Inst); Millennium (Inst); Novartis (Inst) |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Janssen; Merck; Millennium; Onyx; Sanofi |
Research Funding - Celgene; Millennium; Onyx |
Travel, Accommodations, Expenses - Binding Site; Bristol-Myers Squibb; Celgene; Dava Oncology; Janssen; Millennium; ONYX; PFIZER; Sanofi |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Pfizer; Syntimmune |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Pfizer; Syntimmune |
Research Funding - Bristol-Myers Squibb (Inst); Protagonist Therapeutics (Inst); Syntimmune (Inst) |
Patents, Royalties, Other Intellectual Property - UpToDate |
Expert Testimony - Partners Healthcare |
|
|
Stock and Other Ownership Interests - FACIT.org |
Consulting or Advisory Role - Abbvie; Bayer; GlaxoSmithKline; Pfizer |
Research Funding - Bayer (Inst); Genentech (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Bayer; GlaxoSmithKline |
|
|
Employment - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
|
|
Other Relationship - Parexel |
|
|
No Relationships to Disclose |